RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION-Reference-Cited by-同舟云学术

RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION

Published:2009-09-01 Issue:3 Volume:153 Page:211-214
ISSN:1213-8118
Container-title:Biomedical Papers
language:
Short-container-title:BIOMED PAP

Author:

Papajik Tomas,Pikalova Zuzana,Raida Ludek,Skoumalova Ivana,Vondrakova Jana,Faber Edgar,Prochazka Vit,Kubova Zuzana,Kucerova Ladislava,Pavlik Tomas,Dusek Ladislav,Indrak Karel

Publisher

Palacky University Olomouc

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://biomed.papers.upol.cz/doi/10.5507/bp.2009.035.pdf

Reference19 articles.

1. Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

2. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

3. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cellnon-Hodgkin’s lymphoma: a single institution study

4. Rituximab as Adjuvant to Dose-Dense and High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) as First Line Treatment in Stage III–IV Diffuse Large B-Cell Lymphoma (DLBCL) at Poor Prognosis: Final Analysis of Phase II GIMURELL Trial.

5. Effects of Pretransplantation Treatment With Rituximab on Outcomes of Autologous Stem-Cell Transplantation for Non-Hodgkin's Lymphoma

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study;Transfusion Medicine and Hemotherapy;2023

2. Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma;Chinese Journal of Cancer;2015-09-14

3. Total extract of Korean red ginseng facilitates human bone marrow hematopoietic colony formationin vitro;Blood Research;2014

4. Immune Escape Mechanisms in Diffuse Large B-Cell Lymphoma;ISRN Immunology;2012-12-23

5. A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma;Transfusion;2012-05-25